Hepatic Progenitor Cells and Cells Resistant to Apoptosis in Chronic HCV

Maha M El-Sabaawy*, Eman Abdelsameea1, Ayat R Abdallah2, Ahmed El-Refay2, Mervat Soltan1 and Nemine Ehsan3

1Departments of Hepatology, National Liver Institute, Menoufia University, Egypt
2Epidemiology and Preventive Medicine, National Liver Institute, Menoufia University, Egypt
3Department of Pathology, National Liver Institute, Menoufia University, Egypt

Abstract

Background: Hepatic progenitor cells (HPC) as a hepatic regeneration reservoir, are now signified as one of the promising therapeutics. However, connection to cells resistant to apoptosis in pathogenesis of chronic hepatitis C virus (HCV) is still evolving.

Aim: title relationship between HPC and cells resistant to apoptosis in HCV along with liver disease severity and fibrosis progression. Methods: liver biopsies of 91 chronic HCV patients were immunohistochemically examined. Both demographic and clinical characteristics were sourced from the data registries. METAVIR scoring was unified for both Grading and staging. Immunostaining with CK7, Ki67, and bcl2 antibodies was done.

Results: Transaminases, platelets and prothrombin time exhibited significant relationship with Ki67, CK7 both isolated and ductular and bcl2 both LPT and LAH. CK7 ductular showed association with fibrosis and necroinflammatory activity (P<0.05), while non-significant relation was noticed with the CK7 isolated form and Ki67 (P>0.05). Moreover, bcl2 both LPT and (LAH) demonstrated association with fibrosis and necroinflammatory activity (P<0.05). Positive correlation between immunoexpression of HPCs both isolated (r=0.54, <0.001) and ductular with bcl2 LAH (r=0.476, p<0.001) was recorded. bcl2 H showed positive correlation with the CK7 isolated form (r=0.476, p <0.001), with no correlation between it and the CK7 ductular (r=0.298, p= 0.003).

Conclusion: Hepatic progenitor cells and cells resistant to apoptosis are conversely interrelated to HCV pathogenesis with a pivotal role in disease severity and progression. It is a notion to be considered in development new therapies of HCV-related chronic liver disease.

Keywords: Hepatic progenitor cells; Cells resistant to apoptosis; HCV; Liver fibrosis

Introduction

HPCs in humans present the potential reservoir of cholangiocyte/hepatocyte differentiation [1,2]. Defective mature hepatocyte regeneration is claimed to be an activation stimulus to HPCs proliferation implying an auxiliary role in parenchymal regeneration [3]. The proliferation of HPC is incremented in the progression of the majority of chronic liver diseases including genetic mutations, viral infections and metabolic disorders [4]. It has been reported that activation of HPC in chronic hepatitis C virus infection (CHC) is coupled to the severity of inflammation, stage of fibrosis along with the concomitant clinical status of liver disease [5]. However, the mechanisms underlying this process with their relation to HCV pathogenesis are still unclear.

Additionally, according to Roskams, the activated HPC in chronic HCV might be the target cell population for carcinogenesis as the telomerase shortened hepatocytes are senescent in advanced cirrhosis [6]. Facts implying an extensive concern on their therapeutic based impacts.

A modulation of proapoptotic and antiapoptotic proteins which is the consequence of ignited immune responses by infections has been considered the decisive stance in mapping liver disease progression [7]. Persistent inflammation with the resultant lymphocytes resistant to apoptosis had been mentioned to be a major backer to both chronicity and severity of liver disease [8]. Most studies considering apoptosis in chronic HCV infection; had validated its pathogenic role as an integrator of host immune response against viral infections [9]. Eminently enhanced hepatocyte apoptosis was found to be interconnected to the inflammation severity, stages of fibrosis, transaminases levels and viral load in CHC patients [10]. Apoptotic markers; Fas, Fas ligand, Fas-associated death domain, caspases 3, 8, and 9, and in-situ apoptosis; were almost always the most studied items in this issue [7]. The BCL proteins as antiapoptotic mediators participating substantially in the apoptotic process; have not been systematically and thoroughly discussed in liver tissue of chronic hepatitis C virus infection (CHC) [9].

Investigating the linkage between the HPCs proliferation and lymphocytes resistant to apoptosis in CHC patients might help in intensifying therapeutic based options offered for those patients. In this study, a semi-quantitative and topographical immuno-histological evaluation of HPCs along with portal and hepatic parenchymal lymphocytes resistant to apoptosis was conducted on liver tissues of patients with CHC. Results were correlated with different demographic and clinicopathologic variables to better understand the pathogenic contribution of HPCs and cells resistant to apoptosis to CHC.

Materials and Methods

Specimen collection

This study included 91 chronic HCV patients. Clinical, demographic, and laboratory data were assembled from the data registry of the outpatient clinics of Hepatology department, National Liver Institute (NLI), Menoufia University, Egypt, from the period

*Corresponding author: Maha El-Sabaawy, Departments of Hepatology, National Liver Institute, Menoufia University, Egypt, Tel: 020482223216; E-mail: maha.ahmed@liver.menofia.edu.eg

Received May 27, 2017; Accepted June 26, 2017; Published June 28, 2017


Copyright: © 2017 El-Sabaawy MM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
between January 2013 until December 2014. Inclusion criteria were: 1- age from 18 years up. 2- Positive HCV-PCR. 3. Genotype 4. 4.- Liver biopsies containing at least 6 portal tracts.

Exclusion criteria

HCV co-infection with hepatitis B, schistosomiasis, and/or non-alcoholic steatohepatitis virus. Paraffin blocks and routinely stained slides from liver biopsies of patients included in this study were retrieved from the archives of the department of pathology of NLI. Adapting to the ethical guidelines of the 1975 Declaration of Helsinki, a written consent was a prerequisite to endorsement in this study along with the approval of the ethical committee of NLI, Menofia University. Histological evaluation of liver biopsies from patients with chronic hepatitis included grading of necroinflammation and staging of fibrosis based on the scoring system proposed by Ishak et al. Grades 1 to 3 was ascribed to minimal, grades 4 through 8 as mild, and grades 9 through 12 as moderate chronic hepatitis. No cases revealed necroinflammatory score more than 12. Stages 1–2 indicated mild fibrosis, stages 3–4 moderate fibrosis, stages 5–6 severe fibrosis/cirrhosis. Steatosis, lymphoid aggregates, bile duct injury, and vascular changes were identified by their presence or absence [11].

Immunohistochemistry

Being placed on positively charged slides, tissue sections were deparaffinized in xylene, rehydrated in a graded series of ethanol, and then incubated with 3% hydrogen peroxide. The method used for immunostaining was streptavidin–biotin amplified system. Slides were rinsed in phosphate-buffered saline (PBS) and then exposed to heat-induced epitope retrieval in citrate buffer solution (pH 6) for 20 minutes. After cooling, the slides were incubated overnight at room temperature with monoclonal CK7 (CODE MS-1352-P Thermoscientific OV-TL 12/30), or monoclonal Ki67 (CODE IR626, Dako MIB-1) or monoclonal bcl-2 (CODE MS-123-P1 Thermoscientific 100/DS). (100 µg concentrated and diluted with PBS in a dilution 1:100. Positive tissue controls were bile ducts in liver tissue (built in control) for CK7, pancreatic adenocarcinoma for Ki67 and lymphoma for bcl2. Detection of immunoreactivity was carried out using the ultra-vision detection system, ready-to-use anti-polyvalent horseradish peroxidase/diaminobenzidine (NeoMarkers, LabVision, California, USA). Finally, the reaction was visualized by an appropriate substrate/chromogen (diaminobenzidine) reagent. A counter stain was carried out using Mayer’s hematoxylin. The staining procedure included negative controls for non-specific immunoreaction and a reaction was expressed by brownish coloration of the cytoplasm for bcl-2. Under a microscope, lymphocyte percentage was calculated (the number of positive immunoreaction cells in ratio to 100 cells) in five portal tracts; lymphocytes related to portal tracts (LPT) and five fields of hepatic parenchyma; lymphocytes associated hepatic parenchyma (LHP) at magnification x400 per slide. Immuno-reactive lymphocytes for bcl-2 were scaled from 1 to 3. Number of immunoreactive cells less than 10 were scored as 1, from 11 to 50 scored as 2 and number of positive cells more than 50 were scored 3 (Table 1) [15].

Statistical analysis

Data has been collected and entered into the computer using SPSS (Statistical Package for Social Science) program for statistical analysis, (version 20; Inc., Chicago, IL). Two types of statistics were done:

1. Descriptive statistics: Where quantitative data has been shown as mean, and SD.

2. Analytical statistics: Student t-test was used to compare mean and SD of 2 sets of quantitatively normally distributed data, while Mann-Whitney test was used when this data is not normally distributed. Spearman’s correlation has been used to study the correlation between two variables having not normally distributed data. P-value was considered statistically significant when it is less than 0.05.

Results

Clinical, laboratory and histopathological characteristics

The entire cohort (91 patients) was mainly formed of males (62.6%) with a mean age of 40.06 ± 8.99 years. Liver function tests were within normal ranges, except for mild elevations of transaminases (AST: 46.9 ± 40.6; ALT: 47.1 ± 35.9 IU/ml) with positive HCV-RNA with a level of viremia ranged from 837449.95 ± 1672800.563 IU/ml.

Histopathological evaluation of liver biopsy: most cases exhibited mild necroinflammatory activity (68.7%), mild fibrosis (82.4%), and no steatosis (87.5%).

Imuno-histochemical studies

This study demonstrated the relationship between CK7, Ki67 and bcl-2 immunoreactive cells with the laboratory variables of all patients. Hepatic progenitor cell markers CK7 and Ki67 showed negative correspondence with any of laboratory data including transaminases (AST, ALT) platelets and prothrombin time (p>0.05). However, Bcl2 both LPT and LHP showed significant converse connection with prothrombin time, INR, and platelets (p<0.05).

A ductular form of HPCs revealed 74.1%, and 25.9% in mild and moderate fibrosis respectively, while the isolated form of HPC revealed 76.9% and 23.1% in mild and moderate fibrosis respectively with significant relation (p-value <0.005) (Table 2 and Figure 1).

Regarding Ki67 immunoreaction, it presented in 72.7% and 27.3% in mild and moderate necroinflammation respectively with no significant difference (p=0.543) (Table 2 and Figure 2).

In relation to necroinflammation; HPCs were found to be expanded in most patients of the ductular form, while the isolated form expanded in all patients. The ductular expansion in higher grades of necroinflammation was 16%, 69%, 13.6% and 1.2% in minimal, mild, moderate and severe necroinflammation, respectively, with (p=0.525). However, the isolated form of HPCs expansion increased significantly with grades of the necroinflammatory activity. Isolated form of HPCs were 15.4%, 71.4%, 12.1%, and 1.1% in minimal, mild, moderate and severe necroinflammation, respectively (Table 2, Figures 1 and 2).

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Code</th>
<th>Company</th>
<th>Experimental Tool</th>
<th>Clone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ki-67</td>
<td>IR626</td>
<td>Dako</td>
<td>Monoclonal mouse</td>
<td>MIB-1</td>
</tr>
<tr>
<td>CK7</td>
<td>MS-1352-P</td>
<td>Thermoscientific</td>
<td>Monoclonal mouse</td>
<td>OV-TL 12/30</td>
</tr>
<tr>
<td>BCL-2</td>
<td>MS-123-P1</td>
<td>Thermoscientific</td>
<td>Monoclonal mouse</td>
<td>100/DS</td>
</tr>
</tbody>
</table>

Table 1: Antibodies used in the current study.
Ki67 showed a non-significant relation to necroinflammatory grades (13.6%, 70.5%, 15.9% and zero) in minimal, mild, moderate and severe necroinflammation, respectively (p value>0.005) (Table 2 and Figure 2).

**Relation of antiapoptotic cells with fibrosis and necroinflammatory activity**

Bcl2 immunoreaction in LPT and LHP were 20.4%, 73.4%, 6.3%, zero and 25.5%, 70.6%, 3.9% and zero in minimal, mild, moderate and severe necroinflammation. Bcl2 LPT and LHP were found to be significantly correlated with the necroinflammatory activity according to Ishak score (p-value 0.007, and 0.002). The more advanced necroinflammation the less the presence of bcl2 LPT and bcl2 LHP (Table 2 and Figure 3).

**Table 2:** Association of laboratory and histopathological data to the HPCs and cells resistant to apoptosis patients (n=91).

<table>
<thead>
<tr>
<th>Variables</th>
<th>CK7 ductular P-value</th>
<th>CK7 isolated P-value</th>
<th>BCL2 LPT P-value</th>
<th>BCL2 LHP P-value</th>
<th>Ki 67 P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean+SD</td>
<td>Mean+SD</td>
<td>Mean+SD</td>
<td>Mean+SD</td>
<td>Mean+SD</td>
<td>Mean+SD</td>
</tr>
<tr>
<td>Albumin</td>
<td>4.4±0.42</td>
<td>4.2±0.37</td>
<td>0.048</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>PT*</td>
<td>93.5±3.9</td>
<td>89.9±9.9</td>
<td>0.252</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>INR</td>
<td>1.1±0.03</td>
<td>1.1±0.12</td>
<td>0.281</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Platelets</td>
<td>220.1±42.5</td>
<td>199.3±55.5</td>
<td>0.258</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>ALT*</td>
<td>59.5±19.4</td>
<td>61.9±46.3</td>
<td>0.295</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>AST*</td>
<td>69.6±67.3</td>
<td>50.3±32.3</td>
<td>0.286</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

*PT: Prothrombin, AST: Aspartate Transaminase ALT: Alanine Transaminase

**Figure 1:** Immunostaining of CK7 of chronic HCV liver tissue showing IPC and DPC as shown by arrows. [Original magnification: 200x].

**Figure 2:** Immunostaining of Ki67 of chronic HCV liver tissue showing IPC and DPC as shown by arrows. [Original magnification: 200x].

**Figure 3:** Immunostaining of bcl-2 of chronic HCV liver tissue. [Original magnification: 200x].
and 0.001). Bcl-2 expression in LPT was absent in 87.5 and 12.5 in mild and moderate fibrosis. Also, bcl2 expression in LHP was absent in 96.1, and 47.5 in mild and moderate fibrosis (Table 2 and Figure 3).

Correlation studies between HPC and anti-apoptotic markers: a positive correlation was substantiated between HPC and markers of anti-apoptotic cells and was verified as followed: Bcl2LAH was positively correlated with CK7isolated (r=0.547, p<0.001), and with CK7 ductular (r=0.476, p<0.001). Bcl2LAH was positively correlated with CK7 isolated (r=0.476, p<0.001), while bcl2 was found to be negatively correlated with CK7 ductular (r=0.289, p=0.003) (Table 3).

### Discussion

Studying the pathogenic events evolving in HCV chronicity was, still and will be the most appealing issue attracting hepatologists allover. In spite of the high incidence of HCV in Egypt; data assigning the virus pathogenesis in this special population are insufficient. Hepatocyte regeneration added to apoptosis is two eminent elements portraying chronic HCV natural history events. However, the interconnection linking both axioms is still unclear.

Expansion of HPC was ascribed by Spee et al., with the predilection towards the hepatocytic lineage, suggesting the state of these cells during this chronic lower degree of hepatocyte damage [16].

The relationship between HPCs and the grade of necroinflammatory activity has been a subject of controversy. Some authors reported a significant association between HPCs and grade of activity [17-21]. In this study, despite being insignificant, HPCs were found to be expanded in most patients in the ductular form, while the isolated form was expanded in all patients. The ductular, and isolated expansion along with ki67 were reported to be augmented in a mild grade of necroinflammation according to Ishak grading (69%, 71.4%, and 70.5%), respectively. It is claimed that the inflammatory pathway mediates the response of HPCs in HCV [22]. Likewise, the three markers of HPCs expansion were found to be boosted in patients with moderate fibrosis than those with milder stages (74.1, % and 25.9%, 76.9%, and 23.1%), and (72.7% and 27.3%) respectively. Consequently, we could conclude that the number of HPCs is increased significantly with the progression of fibrosis. This agrees with several investigators [4,8,19,23]. It is hypothesized that blocking of the proliferative activity of HCV-infected hepatocytes leads to activation of HPCs which in turn promote the fibrogenesis cascade [7]. Another explanation based on the hypothesis implying that replication exhaustion of hepatocytes in patients with HCV pathogenesis. Nevertheless, the mechanisms involved in such an association are not yet clear. o elucidates the mechanism by which interferon alpha treatment reduced the numbers of intermediate hepatocellular carcinoma in cirrhotic HCV patients supported by the anti-apoptotic/oncogenic probability of bcl-2 [29]. El-Bendary et al. had studied apoptosis in HCV infection associated with bilharziasis spotting light on the presence of apoptotic (fas) and antiapoptotic (Bcl2) markers [32]. In spite of being statistically insignificant Bcl2 was found to be lessened accompanying disease progression and severity in HCV patients.

To be genuine, in our cohort the converse interplay between the two elements of this study: HPC expansion and cells resistant to apoptosis was evident. This complementary harmonized counter connection might be potentially incriminated in chronic HCV pathogenesis. Nevertheless, the mechanisms involved in such an association are not yet clear. o elucidates the mechanism by which interferon alpha treatment reduced the numbers of intermediate hepatobiliary cells present in the chronic hepatitis C patients, we examined the effects of pegylated interferon alpha 2b on the proliferation, apoptosis, and differentiation of two well-characterized murine oval cell lines. The results suggest that interferon may exert direct effects on hepatic progenitor cells, reducing their rate of cell growth as well as stimulating them to undergo apoptosis [33]. This is in accordance with the observed effects of interferon on human HCC-derived cell lines, in which interferon alpha caused delayed S-phase progression through inhibition of cyclin-dependent kinases [34] and induced caspase-dependent apoptosis [35].

### Table 3: Correlation between HPC and markers of anti-apoptosis.

<table>
<thead>
<tr>
<th>Variables</th>
<th>BCl2LAH Correlation Coefficient (r)</th>
<th>P-value</th>
<th>BCl2H Correlation Coefficient (r)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK7 isolated</td>
<td>0.547</td>
<td>&lt;0.001</td>
<td>0.476</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CK7 Ductular</td>
<td>0.476</td>
<td>&lt;0.001</td>
<td>0.289</td>
<td>0.003</td>
</tr>
</tbody>
</table>

HH signal released by dying hepatocyte could activate the compensatory outgrowth of hepatic progenitors, which are involved in liver regeneration [35]. As a HH target, osteopontin is highly expressed in fibrotic liver tissue and influences the function of hepatic progenitors [34]. HOWEVER, neutralization of osteopontin could suppress progenitor cell response and attenuate liver fibrosis in CCl4, methionine-choline-deficient diet (MCD) and 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet (DDC) mice. These suppositions might open new horizons in HCV pathogenesis understanding [36].

Conclusion

As a reservoir of hepatic tissue, the substantial role of HPC in liver cells renewal is unquestionable especially in the era of direct antiviral drugs which are mainly concerned with viral eradication rather than restoration of liver vitality. The hypothesized linkage between HPC expansion and cells resistant to apoptosis in chronic HCV patients should be more emphasized for a better advantageous revival of therapeutic options in these cohorts. A new role for antipapoptotic along with HPC antagonists might be advocated; paving the way for halting the predestined progression of a HCV-related chronic liver disease. However, further research is recommended to investigate the mechanisms underlying such an association.

References